Form 4: Fennec Pharmaceuticals Director Rosty Raykov Reports Share Acquisition and Disposal

Director Rosty Raykov reports acquiring and disposing of Fennec Pharmaceuticals common shares on February 28, 2025, resulting from the release of restrictions on previously awarded shares.

Summary

• On February 28, 2025, Rosty Raykov, a director of Fennec Pharmaceuticals, reported a transaction involving the company's common shares.
• Raykov acquired 2,431 shares and disposed of 78,725 shares.
• The acquisition was priced at $0.
• These transactions relate to the release of restrictions on shares awarded on March 31, 2023.
• Following the reported transactions, Raykov still beneficially owns common shares of Fennec Pharmaceuticals.

Sentiment

Score: 5

Explanation: This is a neutral report of insider trading activity, specifically the release of restrictions on previously awarded shares. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It allows investors to monitor the actions of key individuals within the company.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company directors as an indicator of management's view of the company's prospects.

Key Dates